Clinical Trial Update: Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibrutinib in symptomatic, previously untreated Waldenstrom's macroglobulinemia with analysis of tumor genomic evolution using whole gen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2022-01-12